drugset / Trial / NCT04308889
Pro-Resolving Mediators in Acute Inflammation in Humans
Phase 0
Completed
19 enrolled
Brigham and Women's Hospital
National Institute of General Medical Sciences (NIGMS) · collab
Non-randomizedCrossoverOpen-labelBasic science
Summary
The investigators are undertaking a clinical blister model with or without dietary supplementation with omega-3 fatty acids (i.e., Lovaza) to determine the role of specialized pro-resolving mediators - endogenous lipids converted from omega-3 fatty acid precursors including those in Lovaza - on inflammation parameters and their resolution.
Timeline
- Start
- 2018-07-02
- Primary completion
- 2022-02-03
- Completion
- 2022-02-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lovaza | Other / unclassified | 4 g | Oral |